About: Basic immunology may lead to translational therapeutic rationale: SARS‐CoV‐2 and rheumatic diseases

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Basic immunology may lead to translational therapeutic rationale: SARS‐CoV‐2 and rheumatic diseases Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Basic immunology may lead to translational therapeutic rationale: SARS‐CoV‐2 and rheumatic diseases
Creator	Alivernini, Stefano Ferraccioli, Gianfranco Ferraccioli, Edoardo Gremese, Elisa Tolusso, Barbara
Source	Medline; PMC
abstract	COVID‐19 pandemia is a major concern for patients and healthcare systems. The fear of infection by patients with concomitant rheumatic diseases (either adult or children) and connective tissue diseases is arising worldwide, because of their immunological background and immunological therapies. Analysing the basic biology of single diseases, the data suggest that there is an %22immunological umbrella%22 that seems to protect against the infection, through IFN type 1 and NK cell function. To date, reports from China, United States and Europe did not reveal an higher risk of infection, either for rheumatoid arthritis, juvenile idiopathic arthritis nor for lupus erythematosus. Antimalarials, anti‐IL6‐Anti‐IL6 receptor, anti‐IL1, anti‐GM‐CSF receptor and JAK1/2/3 inhibitors, are under investigation in COVID‐dedicated clinical trials to control the inflammation raised by SARS‐CoV‐2 infection. Initial reports on the occurrence of autoimmune phenomena in the convalescence phase of SARS‐CoV‐2 infection suggests that the immunological consequences of the infection need to be strictly understood. Reporting of the study conforms to broad EQUATOR guidelines (Simera et al January 2010 issue of EJCI).
has issue date	2020-07-29(xsd:dateTime)
bibo:doi	10.1111/eci.13342
bibo:pmid	32645207
has license	no-cc
sha1sum (hex)	221aab6d1b17b44bcfe5673d55d95f8a6d5d3b90
schema:url	https://doi.org/10.1111/eci.13342
resource representing a document's title	Basic immunology may lead to translational therapeutic rationale: SARS‐CoV‐2 and rheumatic diseases
has PubMed Central identifier	PMC7404583
has PubMed identifier	32645207
schema:publication	Eur J Clin Invest
resource representing a document's body	covid:221aab6d1b17b44bcfe5673d55d95f8a6d5d3b90#body_text
is schema:about of	named entity 'January 2010' named entity 'diseases' named entity 'United States' named entity 'phenomena' named entity 'rheumatic diseases' named entity 'receptor' named entity 'consequences' named entity 'clinical trials' named entity 'COVID-19' named entity 'arising' named entity 'immunology' named entity 'EQUATOR' named entity 'IL6' named entity 'HIGHER' named entity 'JANUARY' named entity 'CONFORMS' named entity 'CONCOMITANT' named entity 'THERAPIES' named entity 'CONVALESCENCE' named entity 'REPORTING' named entity 'NK CELL' named entity 'EITHER' named entity 'RISK OF INFECTION' named entity 'DEDICATED' named entity 'UNDERSTOOD' named entity 'REVEAL' named entity 'adult' named entity 'NK cell' named entity 'therapies' named entity 'background' named entity 'Initial' named entity 'control' named entity 'JAK1' named entity 'umbrella' named entity 'patients' named entity 'infection' named entity 'lupus erythematosus' named entity 'infection' named entity 'inflammation' named entity 'connective tissue diseases' named entity 'autoimmune' named entity 'IL1' named entity 'infection' named entity 'infection' named entity 'IFN' named entity 'NK cell' named entity 'EQUATOR' named entity 'COVID' named entity 'clinical trials' named entity 'SARS-CoV-2' named entity 'IL6' named entity 'SARS-CoV-2' named entity 'infection' named entity 'reveal' named entity 'COVID-19' named entity 'SARS-CoV-2' named entity 'MAS' named entity 'infection' named entity 'DN2' named entity 'IFN-α/β' named entity 'type 1' named entity 'SARS-CoV-2' named entity 'rheumatic disorders' named entity 'steroids' named entity 'SARS-CoV-2' named entity 'ICU' named entity 'rheumatological diseases' named entity 'Tocilizumab' named entity 'SARS-CoV-2' named entity 'serine protease' named entity 'clinical phases' named entity 'antimalarials' named entity 'glycosylation' named entity 'alveolar' named entity 'IL6' named entity 'lung function' named entity 'oral administration'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software